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Abstract
Background:  Accumulating evidence suggests that somatic stem cells undergo mutagenic
transformation into cancer initiating cells. The serous subtype of ovarian adenocarcinoma in
humans has been hypothesized to arise from at least two possible classes of progenitor cells: the
ovarian surface epithelia (OSE) and/or an as yet undefined class of progenitor cells residing in the
distal end of the fallopian tube.
Methods: Comparative gene expression profiling analyses were carried out on OSE removed
from the surface of normal human ovaries and ovarian cancer epithelial cells (CEPI) isolated by laser
capture micro-dissection (LCM) from human serous papillary ovarian adenocarcinomas. The
results of the gene expression analyses were randomly confirmed in paraffin embedded tissues
from ovarian adenocarcinoma of serous subtype and non-neoplastic ovarian tissues using
immunohistochemistry. Differentially expressed genes were analyzed using gene ontology,
molecular pathway, and gene set enrichment analysis algorithms.
Results: Consistent with multipotent capacity, genes in pathways previously associated with adult
stem cell maintenance are highly expressed in ovarian surface epithelia and are not expressed or
expressed at very low levels in serous ovarian adenocarcinoma. Among the over 2000 genes that
are significantly differentially expressed, a number of pathways and novel pathway interactions are
identified that may contribute to ovarian adenocarcinoma development.
Conclusions: Our results are consistent with the hypothesis that human ovarian surface epithelia
are multipotent and capable of serving as the origin of ovarian adenocarcinoma. While our findings
do not rule out the possibility that ovarian cancers may also arise from other sources, they are
inconsistent with claims that ovarian surface epithelia cannot serve as the origin of ovarian cancer
initiating cells.
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Background
Ovarian cancer is the most lethal of all gynecological can-
cers [1]. In the United States alone, an estimated 22,000
women will be diagnosed and 15,000 will die from ovar-
ian cancer in 2009 [2]. Despite the obvious clinical signif-
icance of the disease, the processes that underlie the onset
and progression of ovarian cancer remain among the
most poorly understood of all human malignancies.
It has been estimated that up to 90% of ovarian adenocar-
cinomas are derived from ovarian surface (coelomic) epi-
thelia (OSE) [3,4]. However, in contrast to a
dedifferentiation  origin of adenocarcinomas from more
differentiated cells [5], OSE are proposed to become more
rather than less differentiated as the malignancy
progresses often presenting cellular phenotypes resem-
bling multiple Müllerian or paramesonephric duct
derived tissues (e.g. endosalpingeal, endometrial and
endocervical cells). The lack of morphological similarity
between OSE and ovarian adenocarcinomas has led to
claims that at least the serous subtype of ovarian adeno-
carcinoma is not derived from OSE but rather from an as
yet to be defined, more differentiated cell residing in the
distal end of the fallopian tube [6-9]. Indeed anaplasia
and frank carcinoma are often detected in the distal end of
the fallopian tube in women harboring germline muta-
tions in either the BRCA1 or BRCA2 genes that have been
estimated to account for more than 80% of inherited
breast and ovarian cancers [8-10]. However, the inference
that some ovarian cancers may arise in the fallopian tube
does not detract from compelling evidence that ovarian
cancer may arise from OSE [11]. For example, it has been
recently demonstrated that murine coelomic OSE display
many characteristics of adult stem/progenitor cells, such
as in vivo label retention and in vitro clonogenicity [12].
These findings are consistent with previous studies show-
ing that transformed mouse OSE have the capacity to
serve as progenitor cells and differentiate along distinct
Müllerian lineages leading to cystic tumors that resemble
high-grade serous, endometrioid-like and mucinous-like
adenocarcinomas [13]. The fact that cancer stem cells are
typically embedded within end stage tumors does not
contradict the notion that malignant neoplasms can initi-
ate from the accumulation of mutations in adult stem cell
populations leading to their subsequent transformation
into cancer initiating cells [14]. Indeed, the cancer stem
cell hypothesis is the current resurrection of a long sus-
pected origin for cancer [15] and data are rapidly accumu-
lating that support a stem cell origin of many types of
cancers [16-18]. The fact that mammalian OSE accumu-
late high levels of potentially mutagenic 8-oxoguanine
modifications following each ovulation is consistent with
the proposal that mutant OSE may be the progenitor of
ovarian adenocarcinomas [19,20].
To test the hypothesis that human OSE retain properties
of relatively uncommitted multipotent progenitor cells
until undergoing neoplastic transformation, we con-
ducted gene expression profiling analyses on 12 OSE sam-
ples collected in vivo and 12 samples of laser capture
microdissected cancer epithelia (CEPI) from serous papil-
lary ovarian adenocarcinomas collected from flash frozen
tissue. We find that over 2000 genes are significantly dif-
ferentially expressed between the OSE and CEPI samples.
Consistent with a multipotent phenotype, we found that
genes previously associated with adult stem cell mainte-
nance are highly expressed in OSE. Pathway analysis
implicates key signaling molecules and novel pathway
interactions in ovarian cancer development.
Methods
Tissue Collection for Microarray
All tissues were collected by the Ovarian Cancer Institute
following approved Institutional Review Board protocols
from Northside Hospital and Georgia Institute of Tech-
nology, Atlanta, GA. Normal ovarian surface epithelial
(OSE) cells were collected from ovaries at time of surgery
using a Cytobrush® Plus (Medscand), immediately sus-
pended in RNA later (Ambion), and stored at -20°C. Indi-
cations for removal of healthy ovaries included other
gynecologic pathologies as indicated in Table 1. Tumor
tissues were surgically removed and immediately (<1
minute) placed in cryotubes and snap frozen in liquid
nitrogen. Following pathological verification, twelve
serous papillary cancer samples were embedded in cryo-
matrix (Shandon). Seven micron frozen sections were cut
and attached to uncharged microscope slides for each
sample. Immediately after dehydration and staining (His-
toGene, LCM Frozen Section Staining Kit, Arcturus), slides
were processed in an Autopix Laser Capture Microdissec-
tion instrument (Arcturus) and cancer cells captured on
CapSure MacroCaps. Approximately 30,000 cancer epi-
thelia were collected from each of the twelve cancer sam-
ples.
RNA Extraction and Amplification
RNA was extracted from LCM cells on the MacroCaps in
25 μL of extraction buffer and isolated following PicoPure
RNA Isolation Kit (Arcturus) protocols. OSE cells were
pelleted from RNAlater and RNA was isolated with Trizol
(Invitrogen) and purified with the PicoPure RNA Isola-
tion Kit (Arcturus). RNA quality was verified on the Bio-
analyzer RNA Pico Chip (Agilent Technologies).
Total RNA from each of the above 24 extractions was
amplified using the RiboAmp OA or HS kit (Arcturus) that
maintain the original mRNA representation after two
amplification rounds, enabling accurate gene expression
profiles from ultra small samples. The amplified mRNA
was subsequently labeled using the IVT Labeling KitBMC Medical Genomics 2009, 2:71 http://www.biomedcentral.com/1755-8794/2/71
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(Affymetrix), to produce biotin-labeled mRNA suitable
for hybridizing to GeneChip Probe Arrays (Affymetrix
U133 Plus 2.0).
Microarray Analysis
Affymetrix.CEL files were processed using the Affymetrix
Expression Console (EC) Software Version 5.0. Files were
processed using the default MAS5 3' expression workflow.
All reported microarray data are described in accordance
with MIAME guidelines. The processed and raw data files
for the 24 samples used in this study have been deposited
in the Gene Expression Omnibus (GEO) http://
www.ncbi.nlm.nih.gov/projects/geo/ under the series
number GSE14407. Probe sets that were called absent by
default MAS5 criteria in all 24 samples were removed
before further processing. Probe set results were further
evaluated using Spotfire DecisionSite software Probes
were considered differentially expressed if they had a fold
change value of ≥ 3 and a p-value < .005 (Student's t-test).
This resulted in 2915 probe sets differentially expressed
between the twelve OSE and twelve CEPI samples. These
probe sets were filtered for redundant gene titles
(HGU133AV2_V25_affy_annotation file, 3/17/2008) to
yield 2320 unique genes being represented by the probe
sets. Groups of .CEL files from previous studies were proc-
essed in a similar fashion to identify differentially
expressed genes. U133 Plus 2.0 probesets were converted
to all possible U95 Set probesets using the ID converter
application of Babelomics [21] for comparison with the
Marquez et al. data [22]. The twelve .CEL files used from
Table 1: Patient Samples Analyzed in this Study
OCI # AGE AT TIME 
OF SURGERY
TISSUE FOR 
MICROARRAY
HISTOPATHOLOGY 
OF TUMOR OR 
SURFACE 
EPITHELIUM
STAGE GRADE INDICATION FOR 
REMOVAL OF 
HEALTHY OVARIES
MENOPAUSE 
STATUS
317 59 CEPI serous adenocarcinoma Ic 3 N/A postmenopausal
336 63 CEPI serous adenocarcinoma Ic 3 N/A postmenopausal
367 56 CEPI serous adenocarcinoma II 3 N/A postmenopausal
242 63 CEPI serous adenocarcinoma IIb 3 N/A postmenopausal
183 66 CEPI serous adenocarcinoma III 2 N/A postmenopausal
413 49 CEPI serous adenocarcinoma III 3 N/A postmenopausal
229 58 CEPI serous adenocarcinoma IIIc 3 N/A postmenopausal
369 52 CEPI serous adenocarcinoma IIIc 2 N/A postmenopausal
528 66 CEPI serous adenocarcinoma IIIc 3 N/A postmenopausal
588 71 CEPI serous adenocarcinoma IIIc 2/3 N/A postmenopausal
489 48 CEPI serous adenocarcinoma IIIc-IV 3 N/A perimenopausal
542 61 CEPI serous adenocarcinoma IV 3 N/A postmenopausal
434 41 OSE WNL N/A N/A atypical complex hyperplasia 
in polypoid endometrium
perimenopausal
437 54 OSE WNL N/A N/A cervical adenocarcinoma postmenopausal
440 50 OSE WNL N/A N/A uterine myoma perimenopausal
448 63 OSE WNL N/A N/A uterine myoma postmenopausal
452 51 OSE WNL N/A N/A endometrial 
adenocarcinoma
perimenopausal
463 48 OSE WNL N/A N/A endometrial 
adenocarcinoma
perimenopausal
470 44 OSE WNL N/A N/A endometrial 
adenocarcinoma
premenopausal
475 63 OSE WNL N/A N/A benign simple cyst in right 
ovary; left ovary brushing 
used for microarray
postmenopausal
541 41 OSE WNL N/A N/A adenomyosis uteri and 
endometriosis
perimenopausal
552 41 OSE WNL N/A N/A prophylactic TAH-BSO, 
previous breast and vulval 
cancer and family history
premenopausal
563 66 OSE WNL N/A N/A endometrial 
adenocarcinoma
postmenopausal
567 77 OSE WNL N/A N/A endocervical 
adenocarcinoma
postmenopausal
Abbreviations: CEPI - cancer epithelia; OSE - ovarian surface epithelia; WNL - within normal limits; LMP - last menstrual period; HYST - 
hysterectomy;
TAH-BSO - total abdominal hysterectomy with bilateral salpingo-oopherectomyBMC Medical Genomics 2009, 2:71 http://www.biomedcentral.com/1755-8794/2/71
Page 4 of 14
(page number not for citation purposes)
the expO study downloaded from GEO were
GSM152646.CEL, GSM152724.CEL, GSM102557.CEL,
GSM203795.CEL, GSM203744.CEL, GSM117696.CEL,
GSM203709.CEL, GSM152581.CEL, GSM179822.CEL,
GSM179890.CEL, GSM152659.CEL, and
GSM152654.CEL. The significance of the overlap between
experiments from different groups was calculated by the
hypergeometric distribution statistic calculated in R lan-
guage, an integrated environment for statistical comput-
ing and graphics http://www.r-project.org/.
Immunohistochemistry
Archival formalin fixed, paraffin embedded tissues from
ovarian adenocarcinoma of serous subtype and non-neo-
plastic ovarian tissues were obtained from the files of
Emory University Hospital and Crawford Long Hospital,
Atlanta, GA. Emory University's Institutional Review
Board (IRB) approved the immunohistochemistry screen
of these tissues. The sections (5 microns) were deparaffin-
ized and rehydrated. Antigen retrieval was in citrate buffer
(pH 6) using an electric pressure cooker for 5 min at
120°C with cooling for 10 min before immunostaining.
All tissues were exposed to 3% hydrogen peroxide for 5
min, primary antibodies for 30 min, DAKO ENVISION
system (DAKO Corp) HRP labeled polymer conjugated
with secondary antibody for 30 min, diaminobenzidine
as chromogen for 5 min and DAKO automated (DAKO
AUTOSTAINER) hematoxylin and counterstain for 15
min. Primary antibodies used in this study were anti-
ALDH1A2 (Dr Peter McCaffery, University of Aberdeen,
UK.), LHX9 (Abcam), and SFRP1 (GenWay). All incuba-
tions were performed at room temperature. Between incu-
bations, sections were washed with tris-buffered saline
(TBS) buffer. Cover slipping was performed using the Tis-
sue-Tek SCA (Sakura Finetek USA, Inc.) automatic cover
slipper. Slides were scored by a board certified pathologist
(S.L.). Slides were photographed with an Olympus C5050
digital camera attached to the optical port of an Olympus
BX60 compound microscope.
Results
Over two thousand genes are differentially expressed 
between OSE and CEPI
We generated 24 individual gene expression profiles
(Affymetrix Human Genome U133 Plus 2.0 Arrays) from
12 OSE brushings and 12 CEPI samples isolated by laser
capture microdissection. Relevant histopathologies of the
24 samples are listed in Table 1. A supervised (>3-fold
change, t-test p < .005) differential expression analysis
between the OSE and CEPI samples, yielded 2915 differ-
entially expressed probe sets (see Additional file 1). After
manually removing probe sets corresponding to the same
Affymetrix gene title, 2320 differentially expressed genes
remained (see Additional file 2). Of these, 1210 genes are
highly expressed in CEPI relative to OSE and 1110 are
highly expressed in OSE relative to CEPI. A hierarchical
clustering of the data resulted in a distinct separation
between the OSE and CEPI samples (Figure 1).
Comparison of gene expression profiles with prior studies
To assess the correspondence between our data and other
independently gathered ovarian cancer microarray data
sets, we compared differentially expressed probes (DEPs)
for significant overlaps using the Bonferonni corrected
hypergeometric distribution probability. We first com-
pared our DEPs to those generated after performing an
identical differential expression analysis (>3-fold change,
t-test p < .005) on five normal ovarian surface epithelial
brushings and eleven flash frozen bulk tissue serous ovar-
ian cancers that were previously characterized with the
Affymetrix Human Genome U95 Set of 3' Expression
Arrays [22]. Our analysis of these data resulted in 1000
DEPs. In order to relate our data to that of this earlier
study, all of our DEPs from the U133 Plus 2.0 Arrays were
converted to all possible corresponding probe sets from
the U95 Set, resulting in 3920 probe sets for comparison.
When compared to each other, we detected a statistically
significant overlap (392 probe sets, Bonferonni corrected
p = 1.09E-94).
We also compared our DEPs to findings from a differen-
tial expression analysis of our OSE to twelve serous papil-
lary ovarian cancer bulk tissue microarrays produced
independently by the International Genomics Consor-
tium http://www.intgen.org/ Expression Project For
Oncology (exp O, http://expo.intgen.org/geo/home.do)
using the Affymetrix Human Genome U133 Plus 2.0
Arrays. Comparison of our OSE versus the exp O bulk tis-
sue data resulted in 9942 DEPs. When compared to our
2915 DEPs, a statistically significant overlap (1498 DEPs,
Bonferonni corrected p = 1.19E-252) again was detected.
The DEPs from each of these analyses are presented in
Additional file 3. These DEP comparisons provide evi-
dence for significant concordance between our data set
and those of previous studies. The differences that remain
may be attributable to contaminating stromal, immuno-
logical and/or vascular cells contained in bulk tumor sam-
ples used in the other studies.
Genes differentially expressed between OSE and CEPI are 
involved in canonical cell cycle and signaling pathways
In order to provide a global view of the biological proc-
esses associated with genes differentially expressed
between OSE and CEPI, we searched for enrichment of
functional annotations within the Gene Ontology (GO)
database using the Genomica software package [23]. To
provide sample specific meaning to the differentially
expressed genes, we divided our results into two sets: 1)
genes that were on average significantly up-regulatedBMC Medical Genomics 2009, 2:71 http://www.biomedcentral.com/1755-8794/2/71
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(positive fold change values) in CEPI relative to OSE and,
2) genes that were on average significantly down-regu-
lated in CEPI (negative fold change values) relative to
OSE. The results indicate that 258 GO terms are unique or
significantly enriched (p ≤ 0.05) for genes up-regulated in
CEPI (Figure 1 and Additional file 4). Of these, the most
significant category (p = 1.17E-06) was "M phase" (i.e.,
genes involved in mitosis and cytokinesis). Not surpris-
ingly, the top 19 GO terms for genes up-regulated in CEPI
were directly related to cell division. In contrast, genes up-
regulated in OSE were uniquely enriched for 202 GO
terms typically associated with non-dividing or quiescent
cells (Figure 1 and Additional file 4). Differences in the
expression pattern of signaling pathway ligands, recep-
tors, and downstream transcription factors were used to
establish the status of OSE and CEPI cells in key canonical
signaling pathways.
The cell cycle pathway
Figure 2 overlays differences in gene expression between
OSE and CEPI on the cell cycle pathway. Genes known to
be instrumental in maintaining cells in the G0/G1 phases
of the cell cycle are highly expressed in OSE. For example,
representatives of the transforming growth factor beta
(TGFB) signaling pathway, as well as, cyclin-dependent
kinase inhibitor 1B (CDKN1B) are highly expressed in
OSE. In contrast, genes known to be involved in the tran-
sition from G1 to the S phase of the cell cycle are highly
expressed in CEPI. Examples are the cyclins E1, E2, B2 and
A2 (CCNE1, CCNE2, CCNB2 and CCNA2), as well as,
members of the Origin Recognition (ORC6L) and Mini-
Chromosome Maintenance (MCM2, MCM4 and MCM5)
complexes. The results are consistent with the hypothesis
that OSE are arrested in the G0/G1 phase of the cell cycle
while CEPI are actively replicating.
With the aid of Pathway Express [24], we identified from
our DEPs specific upstream signaling pathways contribut-
ing to the inactive (OSE) and active (CEPI) states of the
cell cycle in ovarian cancer development. Figure 3 illus-
trates the differential expression status of components of
each signaling pathway interpreted from both an OSE and
CEPI frame of reference. Heatmaps depicting both the
log2 expression levels and Z-score normalization of these
individual genes are presented in Additional files 5 and 6.
The TGFB/BMP Pathway
The TGFB/BMP pathway is known to be an important
growth inhibitor of epithelial cells [25]. The results pre-
sented in Figure 2 show that the expression of genes medi-
Hierarchical clustering and gene ontology (GO) enrichment of 2320 genes differentially expressed between ovarian surface epi- thelial cells and ovarian cancer epithelial tissue Figure 1
Hierarchical clustering and gene ontology (GO) enrichment of 2320 genes differentially expressed between 
ovarian surface epithelial cells and ovarian cancer epithelial tissue. The heat map (left) was generated by Z-score 
normalization of log2 expression values from Affymetrix HGU133 Plus 2.0 3. Displayed are the relative expression levels of 
genes (rows) differentially expressed (red = relatively over-expressed; green = relatively under-expressed) in 12 ovarian sur-
face epithelial brushings and 12 laser capture microdissected malignant epithelia samples (columns). Unique, enriched GO 
terms are listed for each set of differentially expressed genes and their statistical significance by false discovery rate (FDR) cor-
rected, hypergeometric distribution p-values. Genes overexpressed in CEPI are labeled as CEPI Genes overexpressed in OSE 
are labeled OSE Genes.BMC Medical Genomics 2009, 2:71 http://www.biomedcentral.com/1755-8794/2/71
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Cell cycle pathway gene expression Figure 2
Cell cycle pathway gene expression. Shown is a GenMAPP http://www.genmapp.org rendering of a modified KEGG 
(Kyoto Encyclopedia of Genes and Genomes, http://www.genome.jp/kegg/) schematic of cell cycle pathway genes. Genes signif-
icantly overexpressed in CEPI relative to OSE are colored red. The execution of the cell cycle is depicted from left to right and 
individual phases identified below by I- beam brackets. Genes involved in maintaining G1 are generally under-expressed in CEPI 
while genes involved in G1 to S progression, G2, and M are over-expressed.BMC Medical Genomics 2009, 2:71 http://www.biomedcentral.com/1755-8794/2/71
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Pathway deregulation in ovarian cancer Figure 3
Pathway deregulation in ovarian cancer. Individual signaling pathways hypothesized to be deregulated in the oncogenic 
transformation of ovarian surface epithelia (OSE) into ovarian cancer epithelia (CEPI). An individual OSE is represented on the 
left with individual pathways (as discussed in the text) labeled adjacent to their respective section of each cell. An individual 
CEPI with the same signaling pathways is represented on the right as a mirror image of the OSE cell. The legend describes the 
colored boxes and lines used to represent expression differences and potential interactions among genes. The juxtapositional 
placement of the two cell halves is meant to emphasize the dichotomous state of signaling between the OSE and CEPI as 
revealed by our gene expression microarrays.BMC Medical Genomics 2009, 2:71 http://www.biomedcentral.com/1755-8794/2/71
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ating TGFB/BMP induced growth inhibition in OSE is
significantly down-regulated in CEPI. For example,
expression of the transforming growth factor, beta 2
(TGFB2), the TGFB2 receptors II and III (TGFBR2,
TGFBR3), disabled homolog 2 mitogen-responsive phos-
phoprotein (Drosophila) (DAB2), bone morphogenic pro-
tein 2 (BMP2), as well as, the BMP receptors BMPR1A, and
BMPR2 are all significantly reduced in CEPI while SMAD6
(mothers against decapentaplegic homolog 6 (Dro-
sophila)), an inhibitory SMAD [26], is highly expressed in
CEPI (Figure 3). Snail 2 (SNAI2) [27-29] is expressed at
high levels in OSE (Figure 3) consistent with the absence
of CDH1 expression in OSE [4]. Extracellular modifiers of
TGFB/BMP signaling, decorin (DCN)[30], and chordin-
like 1 (CHRDL1) are also expressed at high levels in OSE
[31].
The WNT Pathway
The WNT (wingless-type MMTV integration site family
members) signaling pathway has been implicated in a
variety of normal and disrupted developmental processes
such as stem cell maintenance [32], embryonic patterning
and cancer [33,34]. The secreted ligands of the WNT fam-
ily are known to stimulate cellular proliferation through
interactions with their cognate frizzled receptors (FZDs)
but are also found to inhibit cellular proliferation in cell-
dependent contexts [35]. For example, the inhibitors of
differentiation, WNT2B and WNT5A [35,36], are
expressed at significantly higher levels in OSE (Figure 3).
In contrast, WNT7A, an inducer of cellular replication in
the female reproductive tract [37], is highly expressed in
CEPI. The WNT receptor FZD7 that has been shown to be
expressed in embryonic stem cells (ES) and to play a role
in self-renewal capacity of ES cells [38], is highly expressed
in OSE and significantly down-regulated in CEPI. The
high expression of known antagonists of WNT signaling
including WNT5A, DAB2, [39] secreted frizzled related
protein 1, (SFRP1) and secreted frizzled related protein 2
(SFRP2) in OSE indicates that major components of WNT
signaling are attenuated on the surface of the ovary. The
high expression of WNT7A and several FZD receptors in
CEPI alternatively suggests that various components of
WNT signaling are activated in CEPI.
Among the most highly expressed genes in CEPI is Zic
family member 1(ZIC1), an activator of WNT signaling
[40]. ZIC encoding genes have been previously implicated
in cancer development [41] and ZIC1 is known to tran-
scriptionally trans-activate apolipoprotein E (APOE) [42]
- a gene previously implicated in the proliferation and sur-
vival of ovarian cancer cells [43]. Over-expression of ZIC1
in CEPI is significantly correlated with APOE expression
(Pearson's r = +0.65).
The NOTCH Pathway
The complex interactions that exist between signaling
pathways are readily evident in our data. For example, the
WNT pathway is known to have recurrent and consistent
interactions with the NOTCH signaling pathway [44]. The
NOTCH signaling pathway plays an important role in
cell-to-cell communications that regulate multiple cell
differentiation processes during embryonic and adult life
[45]. NOTCH3 has been identified as being frequently
over-expressed in ovarian cancer cells and is thought to
form a juxtacrine signaling loop with the ligand jagged1
(JAG1) produced by mesothelial cells of the intraperito-
neal cavity [46,47]. NOTCH3 over-expression also has
been shown to play a major role in the proliferation of
ERBB2-negative breast cancer cells [48]. Our results dem-
onstrate that NOTCH3 is highly expressed in CEPI and
expressed at significantly lower levels in OSE.
The Hedgehog Pathway
Activation of the Hedgehog (Hh) signaling pathway has
previously been implicated in multiple cancers [33,34].
Consistent with activation of the Hh signaling pathway in
CEPI, our results show that two known antagonists of Hh
signaling, hedgehog interacting protein (HHIP) and
growth arrest-specific 1 (GAS1) [49,50] are expressed at
low levels in CEPI. In addition, genes previously shown to
be inversely regulated following Hh pathway activation in
pluripotent mesenchymal cells (e.g., insulin-like growth
factor 2 (IGF2) is up-regulated while SFRP1 and SFRP2 are
down-regulated) [51], are likewise inversely regulated in
CEPI.
The Retinoid Pathway
Retinoids are vitamin A-derived morphogens that can
directly modulate WNT signaling during normal develop-
ment [52]. The gene with the largest fold decrease (-256×)
in CEPI is aldehyde dehydrogenase 1 family, member A2
(ALDH1A2). This gene encodes an enzyme responsible for
the conversion of retinaldehyde to retinoic acid - a known
marker of lineage specific stem cells [53]. The low levels of
ALDH1A2 in CEPI imply that a deficit of retinoic acid in
these cells may be contributing to ovarian cancer by atten-
uation of the WNT signaling pathway. Other genes known
to modulate the cellular activity of retinoic acid are also
differentially expressed between OSE and CEPI (e.g.,
cytosolic cellular retinoic acid binding proteins (CRABPs)
[54,55] and cytochrome P450s (CYP26A1) [56,57]). The
fact that genes involved in the synthesis/activation of
retinoic acid are not expressed in CEPI while genes
involved in the degradation and/or inhibition of retinoic
acid signaling are expressed in CEPI strongly implicates
alteration of the retinoid signaling pathway in ovarian
cancer development.BMC Medical Genomics 2009, 2:71 http://www.biomedcentral.com/1755-8794/2/71
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Immunohistochemistry validation of differentially expressed genes
Figure 4 affirms the corresponding protein expression lev-
els for a number of the differentially expressed genes iden-
tified by microarray analysis. Immunohistochemistry was
performed on formalin fixed, paraffin-embedded (FFPE)
archived tissue samples selected to contain both ovarian
serous adenocarcinoma and adjacent OSE. Consistent
with the microarray profiles, we found that SFRP1 (Figure
4a), ALDH1A2 (Figure 4b), and LHX9 (Figure 4c and 4d)
are differentially expressed at the protein level between
OSE and CEPI. We are currently performing immunohis-
tochemistry for additional proteins in order to substanti-
ate the activity of the pathways discussed above.
Gene set enrichment analyses identify overlapping gene 
expression signatures of specific cell functions in OSE and 
CEPI
In order to provide a comparative gene expression per-
spective to the differentially expressed genes identified in
our study, we employed Gene Set Enrichment Analysis
(GSEA) to compare our results to a large collection of pre-
viously curated biological experiments (e.g., expression
microarray, predicted cis-regulatory motifs, etc.) [58]. The
Molecular Signatures Database (MSigDB) is the collection
of gene sets for use with GSEA software [58]. Statistically
significant overlaps between differentially expressed gene
sets derived from independent expression microarrays
provide evidence for shared biological functions between
the interrogated experiments. GSEA allows for the ranked
comparison of differentially expressed genes between
independent experiments. Genes from our dataset were
ranked by their average fold difference in expression
between OSE to CEPI. GSEA was then used to identify
gene sets from previously published studies that signifi-
cantly overlap with genes differentially expressed between
CEPI and OSE.
Similarities between OSE and cancer stem cells
The gene set with the highest GSEA normalized enrich-
ment score (NES, -2.58, p = 3.31 e-23) to OSE was
BOQUEST_CD31PLUS_VS_CD31 MINUS_DN (see Addi-
tional file 7). This gene set was derived from previously
reported differences between the transcriptional signa-
tures of stem cell-like (CD31-) and differentiated (CD31+)
adipose tissue cells [59].
The cancer stem cell model posits that only a specific sub-
set of a cancer cell population is able to sustain tumor
growth [60]. Putative ovarian cancer stem cells (OCSC)
have recently been isolated from disaggregated ovarian
serous adenocarcinomas and from ascites fluid [61,62].
The origin of OCSCs has yet to be determined but they
were shown to be CD44+ (Indian blood group), and KIT+
(Zuckerman 4 feline sarcoma viral oncogene homolog)
[61,62]. While our results indicate that CD44 is highly
expressed in OSE and expressed at significantly lower lev-
els in CEPI, KIT expression was found to be low in all of
our samples and thus not differentially expressed. How-
ever, the default Affymetrix MAS5 absent/present calls
detected the presence of KIT in 5 of our 12 OSE samples
but absent in all 12 CEPI samples suggesting that KIT is
expressed in OSE. In addition, we found that KIT ligand
(KITLG), is highly expressed in OSE and significantly
lower expressed in CEPI. These findings indicate that
OCSC and OSE express a number of overlapping genes
and support the notion that OSE could give rise to OCSC.
The capacity for self-renewal in multiple adult stem cell
lineages has been associated with expression of the LIM
homeobox genes [63,64]. Our results demonstrate that
LIM homeobox 1, 2, 6 and 9 (LHX1, LHX2, LHX6 and
LHX9) are differentially expressed between OSE and CEPI.
LHX2  and  9  are highly expressed in OSE and not
expressed in CEPI, whereas LHX1 and LHX6 are expressed
in CEPI and not in OSE.
Similarities between wound healing and CEPI
The gene set with the highest positive GSEA normalized
enrichment score (NES, 3.04, p = 5.9 e-64) to CEPI was
SERUM_ FIBROBLAST_ CELLCYLE (see Additional file 8).
This set was derived from a previously reported overlap
between transcriptional signatures in common between
wound healing and poor cancer prognosis [65]. Many of
the genes from this set that are highly expressed in CEPI
promote entry into and progression through the cell cycle
(e.g., FOXM1, PTTG1, AURKA) and have been previously
associated with stage III epithelial ovarian cancers [66,67].
Discussion
We have found that over 2000 genes are significantly dif-
ferentially expressed between OSE and CEPI. Many of
these genes are known to be involved in the canonical cell
cycle pathway, as well as, signaling pathways previously
implicated in development (i.e., the TGFB/BMP, WNT,
NOTCH, Hedgehog and Retinoid pathways). The fact that
many of the genes highly expressed in OSE have previ-
ously been associated with the maintenance of stem cells
in a quiescent state is relevant to hypotheses on the cellu-
lar origin of ovarian cancer.
Under the dedifferentiation hypothesis of cancer develop-
ment, cancer cells are postulated to be less differentiated
than their progenitor cells but often resemble their tissue
of origin phenotypically [5]. The fact that CEPI appear
more rather than less differentiated than OSE and do not
phenotypically resemble OSE has been offered as evi-
dence that these cells are not the source of CEPI [7]. An
alternative hypothesis is that OSE are stem-cell like and
maintain a degree of pluripotency sufficient to allow them
to morphologically transform during the process of CEPIBMC Medical Genomics 2009, 2:71 http://www.biomedcentral.com/1755-8794/2/71
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development. Our results indicate that many, if not all, of
the OSE cells on the surface of the ovary are not terminally
differentiated but arrested in a quiescent state characteris-
tic of most adult stem cell populations [68]. While our
findings are consistent with the hypothesis that OSE may
retain properties of relatively uncommitted pluripotent
cells until undergoing neoplastic transformation, they do
not preclude the possibility that at least some tumors cur-
rently classified as ovarian may arise from related, yet ana-
tomically distinct sources such as cancer initiating cells
embedded within the fallopian tube [69]. Indeed, our
finding that the OSE molecular profile so closely resem-
bles that of previously identified somatic stem cells and
cancer stem cells suggests that all ovarian cancer initiating
cells, regardless of their proposed tissue of origin, will
likely share many essential characteristics.
The processes by which stem cells self-renew and differen-
tiate are accomplished by a combination of cellular divi-
sion strategies known as symmetric and asymmetric
division [17,70]. Symmetric division gives rise to two
identical daughter stem cells. In contrast, asymmetric divi-
sion results in one stem cell and one progenitor cell with
limited self-renewal potential. Our results, showing that
LHX2 and LHX9 are expressed in OSE supports the notion
that asymmetric cellular division is occurring in OSE. Pro-
genitor cells can subsequently go through several rounds
of cell division before terminating into a mature differen-
tiated cell. Whether or not stem cells self-renew or differ-
entiate is regulated by the microenvironment. A
microenvironment that is conducive to stem cell self-
renewal is referred to as a stem cell niche [16,68]. Stem
cell progeny that remain in a stem cell niche typically dis-
play arrested cell growth/replication and are described as
being quiescent [68,71]. In contrast, stem cell progeny
that exit a stem cell niche typically enter a transient period
of accelerated cell division resulting in large numbers of
cells prior to terminal differentiation.
The above description of stem cells and the niches that
control their division is relevant to OSE because during
the period between ovulations, OSE are quiescent. While
arrested cell growth and division are associated with ter-
minal differentiation, at least some OSE must not termi-
nally differentiate because they reactivate their cell cycle
and proliferate in response to ovulation. Evidence recently
has been presented showing that cells on the surface of the
macaque ovary transition from quiescent to a replicating
phenotype in response to ovulation [72]. Similar phe-
nomena have been previously observed in mice [73-75]
and generally support the notion that ovulation tempo-
rarily disrupts the ovarian surface niche resulting in con-
trolled proliferation.
Our results are consistent with the hypothesis that the sur-
face of the ovary is an interovulatory or facultative stem cell
niche and this suggests that all or many of the resting cells
on the surface of the ovary are not terminally differenti-
ated but arrested in a quiescent state characteristic of adult
stem cell populations [68,71]. We find that a variety of
signaling molecules (including TGFB/BMP and TGFBR
family members, antagonists of the WNT and hedgehog
signaling pathways, as well as members of the retinoid sig-
naling pathway) is expressed at high levels in OSE. The
fact that these molecules previously have been shown to
be integral for the maintenance of stem cell niches in
other organ systems [31,35,71,76,77] indicates that they
are likely performing a similar function on the surface of
the ovary between ovulations. Also consistent with the
Immunohistochemistry of OSE gene products Figure 4
Immunohistochemistry of OSE gene products. Immu-
nohistochemistry was performed on fresh frozen paraffin 
embedded OSE and CEPI tissue samples. Staining with pri-
mary antibodies against (A) secreted frizzled-related protein 
1 (SFRP1), (B) aldehyde dehydrogenase 1 family, member A2 
(ALDH1A2), and (C and D) lim homeobox 9 (LXH9) indi-
cated strong protein expression in OSE (labeled arrow) and 
lower or absent protein expression in CEPI (labeled arrow), 
consistent with mRNA expression values shown in Addi-
tional file 5. Each image is a typical representative from 10 
normal and 10 cancer slides. The slides chosen for display 
contain both CEPI and normal adjacent OSE from the same 
tissue sample.BMC Medical Genomics 2009, 2:71 http://www.biomedcentral.com/1755-8794/2/71
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hypothesis that the surface of the ovary is a type of facul-
tative stem cell niche is our finding that transcription fac-
tors previously implicated in self-renewal and asymmetric
division are expressed in OSE [64,78]. In contrast, genes
expressed in CEPI have been associated with the entry and
progression of cells through the cell cycle [79-84]. Of par-
ticular note, is the high expression of the Cyclin E family
genes (CCNE) in CEPI. It has recently been shown that the
constitutive expression of CCNE in mouse embryonic
stem cells results in an almost nonexistent G0/G1 phase
of the cell cycle [68]. The lack of an extended G0/G1
results in less time for cells to respond to mitogens that
stimulate cellular differentiation. Thus, the elevated
expression of CCNE  in CEPI may contribute to cancer
growth in a similar fashion.
The complex molecular processes underlying the onset
and development of epithelial ovarian cancer is only
beginning to be unraveled. Our results indicate that a
number of key developmental pathways are involved in
the establishment and development of ovarian cancer.
While many of these pathways have previously been
either directly or indirectly implicated in ovarian cancer,
detailed network analyses of our gene expression data led
to the identification of linkages between these pathways
attributable to the altered expression of key regulatory
genes. We believe that the type of detailed network analy-
ses of gene expression data presented in this paper when
combined with next generation sequencing for mutation
analyses of individual ovarian adenocarcinoma genomes
will help expand our understanding of the origins of ovar-
ian cancer and facilitate the development of more effec-
tive therapies.
Conclusion
Accumulating evidence suggests that somatic stem cells
undergo mutagenic transformation into cancer initiating
cells. Our results indicate that OSE express many genes
involved in somatic stem cell maintenance. These findings
are consistent with the hypothesis that human OSE retain
properties of relatively uncommitted multipotent progen-
itor cells until undergoing neoplastic transformation. The
multipotent nature of OSE may contribute to the complex
histological subtypes of epithelial ovarian cancer (e.g.,
serous, endometrioid, clear cell, mucinous and others).
While our findings do not rule out the possibility that
ovarian cancers may also arise from other sources, they are
inconsistent with claims that ovarian surface epithelia can-
not serve as the origin of ovarian cancer initiating cells.
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